Singapore Company Guide

Venture Corporation

Version 22 | Bloomberg: VMS SP | Reuters: VENM.SI

Refer to important disclosures at the end of this report

DBS Group Research . Equity

HOLD (downgrade from BUY)


Last Traded Price (8 May 2020): S\$15.74 (STI: 2,591.88) Price Target 12-mth: S\$15.90 (1% upside) (Prev S\$15.80)

Analyst

Lee Keng LING +65 6682 3703 leekeng@dbs.com

What's New

- Weak 1Q20 performance, below expectations
- Full resumption of production; working with customers to scale up demand-side
- Cut earnings for FY20F/FY21F by 12%/7% on weaker 1Q20, and lower margins
- Downgrade to HOLD on limited upside to TP of \$\$15.90



| Forecasts and Valuation | | | | |
|--------------------------|-------|-------|--------|-------|
| FY Dec (S\$m) | 2018A | 2019A | 2020F | 2021F |
| Revenue | 3,485 | 3,633 | 3,452 | 3,651 |
| EBITDA | 465 | 459 | 412 | 465 |
| Pre-tax Profit | 433 | 420 | 375 | 429 |
| Net Profit | 370 | 363 | 322 | 368 |
| Net Pft (Pre Ex.) | 370 | 363 | 322 | 368 |
| Net Pft Gth (Pre-ex) (%) | 2.4 | (1.9) | (11.4) | 14.4 |
| EPS (S cts) | 128 | 125 | 111 | 127 |
| EPS Pre Ex. (S cts) | 128 | 125 | 111 | 127 |
| EPS Gth Pre Ex (%) | 1 | (2) | (11) | 14 |
| Diluted EPS (S cts) | 128 | 125 | 111 | 127 |
| Net DPS (S cts) | 70.0 | 70.0 | 70.0 | 70.0 |
| BV Per Share (S cts) | 813 | 862 | 903 | 960 |
| PE (X) | 12.3 | 12.6 | 14.2 | 12.4 |
| PE Pre Ex. (X) | 12.3 | 12.6 | 14.2 | 12.4 |
| P/Cash Flow (X) | 17.9 | 19.9 | 15.3 | 17.2 |
| EV/EBITDA (X) | 8.3 | 8.4 | 9.2 | 8.2 |
| Net Div Yield (%) | 4.4 | 4.4 | 4.4 | 4.4 |
| P/Book Value (X) | 1.9 | 1.8 | 1.7 | 1.6 |
| Net Debt/Equity (X) | CASH | CASH | CASH | CASH |
| ROAE (%) | 16.4 | 15.0 | 12.6 | 13.6 |
| Earnings Rev (%): | | | (12) | (7) |
| Consensus EPS (S cts): | | | 116 | 127 |
| Other Broker Recs: | | B: 8 | S: 3 | H: 2 |

Source of all data on this page: Company, DBS Bank, Bloomberg Finance L.P

11 May 2020

Temporary setback

Limited upside to TP, downgrade to HOLD. We continue to believe that given Venture's expertise and its entrenched relationship with the industry leaders in the various technology domains, coupled with its balance sheet strength, the group would emerge stronger from the current crisis and is well-positioned for longer term growth. However, in the near term, the damage to the supply and demand side of the entire technology value chain would take time to heal. We have cut FY20F/FY21F earnings by 12%/7% on the back of the weak 1Q20 results, and lower margin assumption. Share price has done well recently, up 26% from its trough in March to outperform the market's (ST Index) 16% gain during the same period. Given the limited upside to our revised TP of S\$15.90, we downgrade Venture to HOLD.

Where we differ: We remain positive on Venture's ability to continue to invest to enhance its differentiating capabilities within its ecosystems of interest. However, we are cautious in the near term.

Potential catalysts: New products and continued expansion into higher margin segments, and new customers. New business opportunities from customer mergers and acquisitions (M&As) amid the US-China trade war and COVID-19.

Valuation:

Cut to HOLD, TP S\$15.90. Our TP is pegged to 12.5x on FY21F earnings, which is -0.5SD of its 10-year average PE.

Key Risks to Our View:

Weakening client or global growth prospects. A broad global slowdown is likely to impact Venture due to its vulnerability to business cycles. Potential weakening of clients' end-demand and/or the US Dollar (USD) could dampen revenue growth.

At A Glance

| Issued Capital (m shrs) | 289 |
|---------------------------|---------------|
| Mkt. Cap (S\$m/US\$m) | 4,543 / 3,216 |
| Major Shareholders (%) | |
| Wong Ngit Liong | 7.0 |
| Schroders Plc | 7.0 |
| Blackrock | 5.0 |
| Free Float (%) | 81.0 |
| 3m Avg. Daily Val (US\$m) | 20.3 |

GIC Industry: Information Technology / Technology Hardware & Equipment







WHAT'S NEW

Weak 1Q20 performance

Weak 1Q20, below expectations. Venture's 1Q20 was affected by the lockdown measures due to COVID-19. Net profit was down 33.6% on the back of the 27.5% drop in revenue. Net margins fell to 9%, the weakest quarter in the last two years. In comparison, 1Q19 net margin was 9.8% and 10.3% in 4Q19. The disruptions to the global supply chain in China, Malaysia and Singapore, and factory lockdowns in China, Spain, the US and Malaysia, mainly impacted the second half of 1Q 2020.

Overall, 1Q20 revenue and net profit accounted for 18% and 17% respectively of our full year forecasts, below expectations.

Summary of 1Q20 results

| (S\$m) | 1Q20 | 1Q19 | 4Q19 | Y-o-Y | Q-o-Q |
|-------------------|-------|-------|-------|---------|---------|
| Revenue | 673 | 928.8 | 932.1 | -28% | -28% |
| Profit before tax | 69.9 | 106.2 | 109.9 | -34% | -36% |
| PBT margin | 10.4% | 11.4% | 11.8% | -1ppt | -1.4ppt |
| Taxation | -9.6 | -15.4 | -13.6 | -38% | -29% |
| Net profit | 60.3 | 90.9 | 96.3 | -34% | -37% |
| Net margin | 9.0% | 9.8% | 10.3% | -0.8ppt | -1.3ppt |

Source: Company, DBS Bank

Stronger cash position. Net cash position as at end-1Q20 improved 19.5% y-o-y to \$\$852.5m. This works out to \$\$2.94 per share or c.19% of its current market capitalisation. Venture's strong net cash position should support expectations that the 70-Sct DPS can be sustained going forward. This represents 4.4% yield based on its current share price.

Full resumption of production; working with customers to scale up demand-side. Venture's businesses are deemed as suppliers of both "essential products" as well as "essential services". By end April, most if not all its operating entities received exemptions to operate without headcount or working hours constraints.

Venture is working closely with its customers/partners to scale up the demand side. Venture continues to see strengths in demand for services and products in technology domains such as Life Science, Healthcare & Wellness, Semiconductor-related Equipment, Communications and Networking modules and products, Diagnostic and Research equipment, and Instrumentation for Test & Measurement.

Strong demand for products used to help COVID-19 infected individuals and advantage. There is strong demand for Venture's products that are being used to help COVID-19-infected individuals, such as ventilators and DNA molecule

testing and monitoring equipment, including those used for next-gen sequencing and the related supply chains.

Beneficiary of realignment of the global supply chain. The COVID-19 pandemic could push companies to diversify their supply chain network, especially out of China, which accounts for the bulk of the global manufacturing output. Venture, with its strong footing in both Malaysia and Singapore, should benefit from this diversification trend in the medium term.

Cut earnings for FY20F/FY21F by 12%/7%; downgrade to HOLD. We have cut earnings for FY20F/FY21F by 12%/7% to account for the weaker 1Q20 results and lower margins. Our target price is raised to S\$15.90 (previously S\$15.80), as we rolled forward to FY21F earnings but still pegged to 12.5x, which is -0.5SD of its 10-year average PE. Share price has done well recently, up 26% from its trough in March, to outperform the market's (ST Index) 16% gain during the same period. Given the limited upside to our revised TP, we downgrade Venture to HOLD.

We continue to believe that given Venture's expertise and its entrenched relationship with industry leaders in the various technology domains, coupled with its balance sheet strength, Venture would emerge stronger from the current crisis and is well-positioned for longer term growth.

Venture 10-year forward PE Band



Source: DBS Bank



CRITICAL DATA POINTS TO WATCH

Critical Factors

Net margin critical in driving share price, well supported by changing business mix. According to our critical factor analysis, Venture's net margins have a direct correlation with its share price. Its evolving business mix, with increasing contribution from the Test & Measurement, Medical & Devices and Life Science clusters and declining contribution from Computer Peripherals and Printing, is likely to improve its margins.

We believe that the specialised nature of the Medical and Life Science segment permits Venture to realise better margins on contracts. Coupled with higher operational efficiencies, this should continue to drive margins higher ahead.

Growing exposure to attractive, high-growth end-markets.

Some of these high-end segments include Test & Measurement, Medical & Devices and Life Science. Venture has established strong relationships with companies researching on genome sequencing, which could see healthy growth over the medium term with increasing investments and use of medical technologies (MedTech).

An increased focus on lower-cost technologies in healthcare is likely to boost the Test & Measurement, Medical & Devices and Life Science segments. This cluster has contributed strongly to the group's top line in recent years, which helped offset the weak performance from the Computer Peripherals & Data Storage segments. Growing exposure to these high-growth segments should lead to higher earnings growth.

Investments in R&D. A key differentiating factor for Venture from its peers is its strong research and development (R&D) capabilities. It has been pursuing innovation and technical competencies, building depth and density in engineering and R&D, as well as manufacturing operations and processes to create distinct differentiators in its technology services, products and solution offerings.


Acquisition of new sites for future expansion.

Venture has acquired a freehold site in Milpitas (California) within the Silicon Valley. This will further enhance its ability to cater to its US customer cluster and creates opportunities for future growth. Venture has also acquired a plot of land with an industrial building in Tebrau, Johor in Malaysia. This will fortify the group's strong foothold in Southeast Asia.






Quarterly net margin trend (%)









Balance Sheet:

Strong balance sheet. Venture's net cash position had at least tripled since FY15 to c.S\$852.5m as at end-1Q20, which should support its 70-Sct DPS going forward

Share Price Drivers:

Expect more volatility ahead. With the cloudy outlook and shortened visibility from the ongoing trade war, and now, the COVID-19 outbreak, we expect more volatility for Venture's share price. The ability to sustain net margins above the 10% level is one of the key factors to watch out for.

Venture is working closely with its customers/partners to scale up the demand-side and will be supporting several partners in their new and key product launches. The group's strategy of pursuing the more resilient Test & Measurement, Medical & Devices and Life Science clusters has been successful in generating revenue and profits for the longer term.

Key Risks:

Dependent on global market conditions. With exposure to customers in the US, European Union (EU) and Asia, a broad global slowdown is likely to impact Venture due to its vulnerability to business cycles. A possible weakness in the Eurozone arising from political instability or restrictive trading policies by the US could weaken global growth prospects. Deterioration in the world economy could affect corporate spending and adversely impact Venture's results.


Weak USD could affect top line. A weakening USD against the Singapore Dollar (SGD) and a prolonged accommodative monetary policy could impact Venture's earnings. Our sensitivity analysis shows that every 1% appreciation of USD against SGD will increase Venture's net profit by ~1.9%.


Environment, Social, Governance:


Venture issued its first sustainability report in 2017. Although its environmental, social and governance (ESG) score is below its peers, improving its sustainability performance is an ongoing process. In FY18, Venture introduced several sustainability initiatives, such as the launch of the Learning Management System, investing in energy efficiency solutions and enhancing policies and practices to safeguard confidential information.

Company Background


Venture Corporation (Venture) is a global provider of technology products and solutions. It is best known for its superior capabilities in Original Design Manufacturing (ODM) and providing high-mix, high-value and complex manufacturing.















Key Assumptions

| FY Dec | 2017A | 2018A | 2019A | 2020F | 2021F |
|----------------|-------|-------|-------|-------|-------|
| Net margin (%) | 9.31 | 10.6 | 9.99 | 9.32 | 10.1 |
| % of SGA (%) | 13.5 | 15.2 | 13.7 | 13.5 | 13.4 |

Segmental Breakdown

| FY Dec | 2017A | 2018A | 2019A | 2020F | 2021F |
|---|-------|-------|-------|-------|-------|
| Revenues (S\$m) | | | | | |
| Advanced Manufacturing & Design Solutions (AMDS) | 3,205 | 2,600 | 2,775 | 2,637 | 2,795 |
| Technology Products & Design Solutions (TPS) | 800 | 885 | 858 | 815 | 856 |
| Total | 4,005 | 3,485 | 3,633 | 3,452 | 3,651 |

Income Statement (S\$m)

| FY Dec | 2017A | 2018A | 2019A | 2020F | 2021F |
|-----------------------------|---------|---------|---------|----------|----------|
| Revenue | 4,005 | 3,485 | 3,633 | 3,452 | 3,651 |
| Cost of Goods Sold | (3,039) | (2,531) | (2,727) | (2,623) | (2,745) |
| Gross Profit | 965 | 954 | 907 | 828 | 905 |
| Other Opng (Exp)/Inc | (537) | (529) | (497) | (465) | (488) |
| Operating Profit | 428 | 425 | 410 | 363 | 417 |
| Other Non Opg (Exp)/Inc | 3.80 | 9.21 | 11.0 | 11.0 | 11.0 |
| Associates & JV Inc | 1.67 | (0.1) | 0.04 | 0.04 | 0.04 |
| Net Interest (Exp)/Inc | (1.0) | (1.0) | (0.5) | 0.0 | 0.0 |
| Exceptional Gain/(Loss) | 11.4 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Profit | 444 | 433 | 420 | 375 | 429 |
| Tax | (71.1) | (62.9) | (56.6) | (52.4) | (59.9) |
| Minority Interest | 0.12 | 0.0 | (0.3) | (0.3) | (0.3) |
| Preference Dividend | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 373 | 370 | 363 | 322 | 368 |
| Net Profit before Except. | 361 | 370 | 363 | 322 | 368 |
| EBITDA | 480 | 465 | 459 | 412 | 465 |
| Growth | | | | | |
| Revenue Gth (%) | 39.3 | (13.0) | 4.3 | (5.0) | 5.8 |
| EBITDA Gth (%) | 82.3 | (3.2) | (1.2) | (10.4) | 13.1 |
| Opg Profit Gth (%) | 103.1 | (0.7) | (3.6) | (11.3) | 14.8 |
| Net Profit Gth (Pre-ex) (%) | 100.1 | 2.4 | (1.9) | (11.4) | 14.4 |
| Margins & Ratio | | | | | |
| Gross Margins (%) | 24.1 | 27.4 | 25.0 | 24.0 | 24.8 |
| Opg Profit Margin (%) | 10.7 | 12.2 | 11.3 | 10.5 | 11.4 |
| Net Profit Margin (%) | 9.3 | 10.6 | 10.0 | 9.3 | 10.1 |
| ROAE (%) | 18.1 | 16.4 | 15.0 | 12.6 | 13.6 |
| ROA (%) | 12.6 | 11.7 | 11.2 | 9.7 | 10.7 |
| ROCE (%) | 16.9 | 15.9 | 14.5 | 12.1 | 13.2 |
| Div Payout Ratio (%) | 45.7 | 54.7 | 55.8 | 63.1 | 55.1 |
| Net Interest Cover (x) | 422.9 | 432.6 | 783.0 | 34,327.1 | 39,407.1 |





| Quarterly | y / Interim | Income Statement | (S\$m) | |
|-----------|-------------|-------------------------|--------|--|
|-----------|-------------|-------------------------|--------|--|

| FY Dec | 4Q2018 | 1Q2019 | 2Q2019 | 3Q2019 | 4Q2019 |
|-----------------------------|--------|---------|---------|---------|---------|
| Revenue | 906 | 929 | 903 | 869 | 932 |
| Cost of Goods Sold | (662) | (702) | (678) | (652) | (694) |
| Gross Profit | 244 | 227 | 225 | 217 | 238 |
| Other Oper. (Exp)/Inc | (122) | (118) | (115) | (116) | (122) |
| Operating Profit | 122 | 104 | 103 | 95.6 | 107 |
| Other Non Opg (Exp)/Inc | 2.88 | 2.48 | 2.66 | 3.15 | 2.71 |
| Associates & JV Inc | 0.0 | 0.0 | 0.04 | 0.0 | 0.0 |
| Net Interest (Exp)/Inc | (0.2) | (0.1) | (0.1) | (0.2) | (0.2) |
| Exceptional Gain/(Loss) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Profit | 124 | 106 | 105 | 98.6 | 110 |
| Tax | (16.8) | (15.4) | (14.5) | (13.2) | (13.6) |
| Minority Interest | 0.0 | 0.0 | (0.1) | (0.2) | 0.0 |
| Net Profit | 108 | 90.9 | 90.8 | 85.2 | 96.3 |
| Net profit bef Except. | 108 | 90.9 | 90.8 | 85.2 | 96.3 |
| EBITDA | 134 | 117 | 116 | 111 | 123 |
| Growth | | | | | |
| Revenue Gth (%) | 17.6 | 2.5 | (2.7) | (3.8) | 7.2 |
| EBITDA Gth (%) | 13.6 | (12.7) | (0.9) | (4.6) | 10.8 |
| Opg Profit Gth (%) | 14.7 | (14.8) | (1.1) | (7.0) | 12.3 |
| Net Profit Gth (Pre-ex) (%) | 33.3 | (15.6) | (0.1) | (6.2) | 13.0 |
| Margins | 07.0 | | | | |
| Gross Margins (%) | 27.0 | 24.5 | 24.9 | 24.9 | 25.5 |
| Opg Profit Margins (%) | 13.4 | 11.2 | 11.4 | 11.0 | 11.5 |
| Net Profit Margins (%) | 11.9 | 9.8 | 10.1 | 9.8 | 10.3 |
| Balance Sheet (S\$m) | | | | | |
| FY Dec | 2017A | 2018A | 2019A | 2020F | 2021F |
| Net Fixed Assets | 198 | 231 | 232 | 245 | 259 |
| Invts in Associates & JVs | 0.79 | 0.73 | 0.76 | 0.80 | 0.83 |
| Other LT Assets | 669 | 667 | 696 | 696 | 696 |
| Cash & ST Invts | 752 | 713 | 714 | 759 | 770 |
| Inventory | 700 | 808 | 706 | 671 | 710 |
| Debtors | 766 | 736 | 899 | 959 | 1,074 |
| Other Current Assets | 58.3 | 49.2 | 25.8 | 25.8 | 25.8 |
| Total Assets | 3,144 | 3,205 | 3,274 | 3,357 | 3,536 |
| ST Debt | 30.8 | 1.80 | 1.06 | 1.06 | 1.06 |
| Creditor | 591 | 529 | 490 | 454 | 468 |
| Other Current Liab | 352 | 320 | 264 | 264 | 264 |
| LT Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other LT Liabilities | 1.72 | 2.06 | 20.4 | 20.4 | 20.4 |
| Shareholder's Equity | 2,166 | 2,350 | 2,496 | 2,615 | 2,780 |
| Minority Interests | 2.31 | 2.23 | 2.40 | 2.40 | 2.40 |
| Total Cap. & Liab. | 3,144 | 3,205 | 3,274 | 3,357 | 3,536 |
| Nico Coll Miles Co. 11 I | 500 | 7.45 | 277 | 007 | |
| Non-Cash Wkg. Capital | 580 | 745 | 877 | 937 | 1,077 |
| Net Cash/(Debt) | 722 | 711 | 713 | 758 | 769 |
| Debtors Turn (avg days) | 67.4 | 78.6 | 82.1 | 98.2 | 101.6 |
| Creditors Turn (avg days) | 66.0 | 81.8 | 69.2 | 66.6 | 62.1 |
| Inventory Turn (avg days) | 80.7 | 110.1 | 102.8 | 97.1 | 93.0 |
| Asset Turnover (x) | 1.4 | 1.1 | 1.1 | 1.0 | 1.1 |
| Current Ratio (x) | 2.3 | 2.7 | 3.1 | 3.4 | 3.5 |
| Quick Ratio (x) | 1.6 | 1.7 | 2.1 | 2.4 | 2.5 |
| Net Debt/Equity (X) | CASH | CASH | CASH | CASH | CASH |
| Net Debt/Equity ex MI (X) | CASH | CASH | CASH | CASH | CASH |
| Capex to Debt (%) | 119.2 | 3,261.4 | 3,281.9 | 4,725.9 | 4,725.9 |
| Z-Score (X) | 6.4 | 5.9 | 6.3 | 6.4 | 6.4 |






Cash Flow Statement (S\$m)

| FY Dec | 2017A | 2018A | 2019A | 2020F | 2021F |
|------------------------|--------|-------------|--------|--------|--------|
| Pre-Tax Profit | 444 | 433 | 420 | 374 | 428 |
| | 46.4 | 455 30.7 | 38.7 | 36.3 | 36.3 |
| Dep. & Amort. | | | | | |
| Tax Paid | (50.3) | (56.3) | (61.5) | (52.4) | (59.9) |
| Assoc. & JV Inc/(loss) | (1.7) | 0.06 | 0.0 | 0.0 | 0.0 |
| Chg in Wkg.Cap. | 13.8 | (147) | (157) | (60.8) | (140) |
| Other Operating CF | (3.4) | (5.9) | (10.7) | 0.0 | 0.0 |
| Net Operating CF | 449 | 254 | 230 | 297 | 265 |
| Capital Exp.(net) | (36.7) | (58.6) | (34.7) | (50.0) | (50.0) |
| Other Invts.(net) | (15.3) | 1.31 | (1.4) | (0.3) | (0.3) |
| Invts in Assoc. & JV | 31.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| Div from Assoc & JV | 1.08 | 0.03 | 0.0 | 0.0 | 0.0 |
| Other Investing CF | 5.36 | 8.74 | 11.4 | 0.0 | 0.0 |
| Net Investing CF | (14.0) | (48.6) | (24.7) | (50.3) | (50.3) |
| Div Paid | (141) | (230) | (202) | (203) | (203) |
| Chg in Gross Debt | (56.3) | 11.3 | (0.7) | 0.0 | 0.0 |
| Capital Issues | 70.7 | (18.1) | 5.52 | 0.0 | 0.0 |
| Other Financing CF | (25.0) | 0.0 | (8.1) | 0.0 | 0.0 |
| Net Financing CF | (151) | (237) | (205) | (203) | (203) |
| Currency Adjustments | (30.5) | (8.6) | 1.67 | 0.0 | 0.0 |
| Chg in Cash | 253 | (39.6) | 1.64 | 44.3 | 11.5 |
| Opg CFPS (S cts) | 153 | 139 | 133 | 124 | 140 |
| Free CFPS (S cts) | 145 | 67.7 | 67.3 | 85.4 | 74.1 |

Source: Company, DBS Bank

Target Price & Ratings History



| S.No. | Date of Report | Closing Price | Target Price | Rating |
|-------|-------------------|------------------|-----------------|--------|
| 1: | 12 Jul 19 | 14.90 | 18.60 | BUY |
| 2: | 13 Aug 19 | 15.28 | 18.60 | BUY |
| 3: | 11 Nov 19 | 15.63 | 17.20 | HOLD |
| 4: | 28 Feb 20 | 16.45 | 18.50 | BUY |
| 5: | 01 Apr 20 | 13.15 | 15.80 | BUY |

Note: Share price and Target price are adjusted for corporate actions.

Source: DBS Bank Analyst: Lee Keng LING



DBS Bank recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 11 May 2020 08:30:56 (SGT) Dissemination Date: 11 May 2020 09:30:03 (SGT)

Sources for all charts and tables are DBS Bank unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd. This report is solely intended for the clients of DBS Bank Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.



Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

- 1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates have a proprietary position in Venture Corporation recommended in this report as of 30 Apr 2020.
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.





RESTRICTIONS ON DISTRIBUTION

| General | This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. |
|-----------|--|
| Australia | This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946. |
| | DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws. |
| | Distribution of this report is intended only for "wholesale investors" within the meaning of the CA. |
| Hong Kong | This report has been prepared by a person(s) who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited, a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore. |
| | For any query regarding the materials herein, please contact Carol Wu (Reg No. AH8283) at dbsvhk@dbs.com |
| Indonesia | This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia. |
| Malaysia | This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies. |
| | God Control of the Co |
| | Wong Ming Tek, Executive Director, ADBSR |
| Singapore | This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn. No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report. |





| Thailand | This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd. |
|---|--|
| United Kingdom | This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore. This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. |
| | In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication. |
| Dubai International Financial Centre | This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608 - 610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it. |
| United Arab Emirates | This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent. |
| United States | This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate. |
| Other jurisdictions | In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. |



DBS Regional Research Offices

HONG KONG DBS (Hong Kong) Ltd

Contact: Carol Wu 13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: 852 3668 4181 Fax: 852 2521 1812 e-mail: dbsvhk@dbs.com

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269

e-mail: research@th.dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission, Thailand

MALAYSIA

AllianceDBS Research Sdn Bhd

19th Floor, Menara Multi-Purpose, Capital Square, 8 Jalan Munshi Abdullah 50100 Kuala Lumpur, Malaysia. Tel.: 603 2604 3333 Fax: 603 2604 3921

Contact: Wong Ming Tek (128540 U)

e-mail: general@alliancedbs.com

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943

e-mail: indonesiaresearch@dbs.com

SINGAPORE DBS Bank Ltd

Contact: Janice Chua
12 Marina Boulevard,
Marina Bay Financial Centre Tower 3
Singapore 018982
Tel: 65 6878 8888

Tel: 65 6878 8888 Fax: 65 65353 418

e-mail: equityresearch@dbs.com Company Regn. No. 196800306E